{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Organovo Holdings, Inc.
Is Organovo Holdings, Inc. overvalued or undervalued?
As of May 10, 2023, Organovo Holdings, Inc. is considered overvalued and has deteriorated to a "does not qualify" rating due to weak financial metrics and significant underperformance compared to peers and the S&P 500.
Is Organovo Holdings, Inc. technically bullish or bearish?
As of June 17, 2025, the technical trend for Organovo Holdings, Inc. has shifted to bearish, with dominant indicators suggesting a negative outlook despite some mixed signals in momentum.
Who are in the management team of Organovo Holdings, Inc.?
As of March 2022, the management team of Organovo Holdings, Inc. includes Mr. Keith Murphy as Executive Chairman and Principal Executive Officer, along with independent directors Mr. Douglas Cohen, Mr. David Gobel, Ms. Alison Milhous, and Mr. Adam Stern.
What does Organovo Holdings, Inc. do?
Organovo Holdings, Inc. is a commercial-stage biotechnology company focused on developing functional human tissues. As of March 2025, it reported net sales of $0 million and a net profit of $7 million, with a market cap of $3.93 million.
How big is Organovo Holdings, Inc.?
As of Jun 18, Organovo Holdings, Inc. has a market capitalization of 3.93 million, with net sales of 0.14 million and a net profit of -2.49 million over the latest four quarters. Shareholder's funds are reported at 10.49 million, and total assets amount to 14.65 million.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
